Every plan awarded NCQA’s health equity standard, state-by-state

Every plan awarded NCQA’s health equity standard, state-by-state

Of the 1,100-moreover wellbeing programs accredited by the National Committee for Top quality Assurance, 61 have gained the well being equity accreditation granted by the association. 

The normal is granted to designs with an organizational concentration on range, equity and inclusion, amassing wellbeing fairness knowledge and reporting outcomes by race and ethnicity. 

Seven plans have acquired the committee’s new overall health equity additionally designation, which contains a lot more expectations for addressing social determinants of wellbeing. 

Below are all of the options that have been granted the designation. 

Arkansas

Summit Group Treatment (Medicaid) 

 

California

Blue Cross of California Partnership Approach (Medicaid) 

Health and fitness Internet (Medicaid, Exchange, Medicare and Industrial) *Accreditation plus 

Molina Healthcare of California Associate Plan (Medicaid and trade) *Accreditation plus 

 

Florida

Aetna Better Overall health of Florida (Medicaid) 

Only Health care Programs, an Elevance Health firm (Medicaid) *Accreditation furthermore

UnitedHealthcare Group Prepare (Medicaid) 

 

Ga

Amerigroup Local community Treatment (Medicaid) 

Peach Condition Overall health System (Medicaid) 

 

Illinois 

Aetna Much better Well being of Illinois (Medicaid) 

 

Indiana

Anthem Blue Cross and Blue Protect (Medicaid)

 

Iowa

Amerigroup Iowa (Medicaid) 

 

Kansas

Aetna Better Wellness of Kansas (Medicaid) 

 

Kentucky 

Aetna Improved Wellness of Kentucky (Medicaid) 

Anthem Kentucky Managed Treatment Prepare (Medicaid) 

 

Louisiana 

Balanced Blue (Medicaid) 

 

Maine

Harvard Pilgrim Healthcare (exchange) 

 

Maryland

Amerigroup Maryland (Medicaid) 

Aetna Much better Health and fitness of Maryland (Medicaid) 

 

Massachusetts

Harvard Pilgrim Healthcare (trade) 

Tufts Health and fitness Designs (exchange and Medicaid) 

 

Michigan

Aetna Better Well being of Michigan (Medicaid) *Accreditation plus 

UnitedHealthcare Community Program (Medicaid) *Accreditation as well as

 

Minnesota

UCare Minnesota (Medicaid) 

 

Mississippi 

Magnolia Wellbeing Prepare (Medicaid) 

 

Missouri

Healthier Blue (Medicaid) 

UnitedHealthcare Neighborhood Approach (Medicaid) 

 

Nebraska

Nutritious Blue (Medicaid) 

Nebraska Whole Treatment (Medicaid) 

UnitedHealthcare Community System (Medicaid) 

 

Nevada 

Anthem Blue Cross and Blue Protect Healthcare Remedies (Medicaid) 

SilverSummit Wellness System (Medicaid, exchange) 

 

New Jersey 

Aetna Greater Wellness of New Jersey (Medicaid) 

UnitedHealthcare Local community Program (Medicaid) 

Amerigroup New Jersey (Medicaid) 

 

New York 

Overall health Moreover HP (Medicaid) 

UnitedHealthcare Group Program (Medicaid) 

 

Pennsylvania

Geisinger Well being Plan (Medicaid) 

Pennsylvania Health and fitness and Wellness (Medicaid) 

UPMC For You (Medicaid) *Accreditation plus 

 

South Carolina 

Absolute Total Care (Medicaid) 

BlueChoice Wellbeing Plan of South Carolina (Medicaid) 

 

Tennessee

Amerigroup Tennessee (Medicaid) 

UnitedHealthcare Local community Prepare (Medicaid) 

 

Texas

Amerigroup Texas (Medicaid) 

Amerigroup Insurance plan Company (Medicaid) 

Scott and White Overall health Prepare (Medicaid) 

UnitedHealthcare Community Approach (Medicaid) 

 

Virginia 

Aetna Improved Well being of Virginia (Medicaid) 

HealthKeepers (Medicaid) 

 

Washington

Amerigroup Washington (Medicaid) 

UnitedHealthcare Community Program (Medicaid) 

 

West Virginia 

Unicare Health and fitness Plan of West Virginia (Medicaid) 

 

Wisconsin 

UnitedHealthcare Neighborhood Strategy (Medicaid) 

Anthem Blue Cross and Blue Defend (Medicaid)

Report details mental health treatment, education | News, Sports, Jobs

Report details mental health treatment, education | News, Sports, Jobs
&#13
&#13

Sammy Jo Hester, Day-to-day Herald file image

Pupils perform with a foster canine throughout UVU’s psychological health and fitness 7 days on Monday, Sept. 26, 2017.

&#13

In 2022, the Huntsman Psychological Wellness Institute saw 16,847 patients at extra than 20 areas across Utah and Idaho trying to get procedure for different disorders ranging from significant depressive dysfunction to suicidal ideation.

On Friday, the Institute launched its 2022 once-a-year report displaying the effects mental well being treatment can have on individuals who are suffering.

“In the earlier yr, HMHI has produced important collaborations with companions in the private and public sector to enhance obtain to mental well being treatment and initiate designs to lower the psychological overall health worker shortage,” mentioned Dr. Mark Rapaport, CEO of HMHI. “We’re functioning across disciplines to acquire improved and new interventions and ways to sophisticated syndromes, stop suicide, and eradicate stigma. Collectively, we can supply hope, therapeutic, and the likelihood for people struggling from weak psychological health to are living the dignified life they have earned.”

In accordance to the report, HMHI is escalating recognition all-around the gaps in psychological wellness providers and earning treatment more obtainable by extending its crisis providers. The institute collaborated with point out and nationwide associates to make certain high-quality of treatment with the rollout of Utah’s 988 mental health crisis line and extending the SafeUT system, which done 349 lifesaving interventions in 2022.

HMHI is also doing work to eradicate social stigma encompassing mental overall health disorders.

“People struggling from psychological wellbeing problems encounter stigma, shame, dread and prejudice, avoiding them from accessing suitable treatment,” the report states. “By supplying a further knowledge of these troubles, we can erase this stigma and supply much more opportunities to advertise and defend psychological overall health.”

In addition, the report shows HMHI is increasing psychological health schooling by giving instruction solutions for crisis staff, nurses and pharmacy inhabitants along with interns majoring in social operate, healthcare aiding and learn of healthcare administration.

“Too lots of of our neighbors, pals, spouse and children customers, colleagues, and fellow individuals are dealing with a intense mental wellness problem,” said David Huntsman, president and chief functioning officer of the Huntsman Psychological Wellbeing Foundation. “We at the basis and HMHI are focused to supplying the psychological well being expert services that people today so desperately need to have. We’re grateful for the donations and partnerships that support us attain our mission.”

The institute will keep on working on psychological health troubles by a few principal courses. They will contain linking treatment and neighborhood providers to provide the most susceptible group associates, empowering scientists to get the job done together throughout disciplines to tackle mental disorders and combating stigma around mental health and material use disorder by encouraging people suffering to get help.

“The Huntsman Foundation recognizes that just about every relatives is touched in some way by anyone who is battling with their psychological wellness,” reported Christena Huntsman Durham, govt vice president of the Huntsman Psychological Overall health Foundation. “We recognize HMHI for their groundbreaking and holistic techniques of treating sufferers. By means of their considerable analysis, HMHI will rework life all around the world. We see no restrictions to what this visionary organization can attain.”

&#13 &#13
&#13
&#13

E-newsletter

&#13

&#13

Be part of 1000’s already getting our every day publication.

&#13
&#13

&#13
&#13
&#13
&#13

Medical Equipment Suppliers Convicted of Health Care Fraud | OPA

Medical Equipment Suppliers Convicted of Health Care Fraud | OPA

A federal jury convicted two adult men these days for engaging in a plan to defraud Medicare Advantage and Medicaid managed treatment strategies of in excess of $3.8 million.

According to court docket documents and proof presented at demo, Ikechukwu Udeokoro, 47, of North Bergen, New Jersey, owned Meik Clinical Gear and Supply (Meik), a durable healthcare gear supplier that was situated in the Bronx, New York. Ayodeji Fasonu, 56, of Bridgeport, Connecticut, was Meik’s manager. Through Meik, Udeokoro and Fasonu billed Medicare Edge and Medicaid managed care strategies for hundreds of costly affected individual guidance methods that have been under no circumstances provided to clients or caregivers. These help units involved huge products that ended up created to support with lifting motionless people and sufferers in nursing properties. In fact, Udeokoro and Fasonu furnished individuals with recliner chairs that experienced a seat elevate characteristic. Amongst December 2010 and February 2014, Udeokoro and Fasonu fraudulently billed Medicare Gain and Medicaid managed care options a lot more than $3.8 million and ended up paid out around $2.4 million.

Udeokoro and Fasonu ended up both of those convicted of health care fraud. They are scheduled to be sentenced on Aug. 14 and Aug. 16, respectively, and each individual faces a maximum penalty of 10 yrs in jail. A federal district court docket judge will identify any sentence just after taking into consideration the U.S. Sentencing Recommendations and other statutory variables.

Assistant Attorney Standard Kenneth A. Well mannered, Jr. of the Justice Department’s Criminal Division U.S. Legal professional Breon Peace for the Jap District of New York Assistant Director Luis Quesada of the FBI’s Criminal Investigative Division Assistant Director in Charge Michael J. Driscoll of the FBI New York Subject Business office and Special Agent in Charge Scott J. Lampert of the Department of Wellness and Human Providers Office of Inspector General’s (HHS-OIG) Business office of Investigations designed the announcement.

The FBI and HHS-OIG investigated the situation.

Demo Lawyers Andrew Estes and Patrick J. Campbell of the Legal Division’s Fraud Part are prosecuting the circumstance.

The Fraud Segment prospects the Criminal Division’s efforts to combat health and fitness treatment fraud by means of the Overall health Care Fraud Strike Drive Application. Considering that March 2007, this plan, comprised of 15 strike forces running in 24 federal districts, has billed much more than 4,200 defendants who collectively have billed the Medicare program for extra than $19 billion. In addition, the Centers for Medicare & Medicaid Products and services, doing the job in conjunction with the Business office of the Inspector Common for the Division of Health and fitness and Human Services, are getting actions to hold vendors accountable for their involvement in health and fitness treatment fraud strategies. Extra details can be found at https://www.justice.gov/felony-fraud/wellness-treatment-fraud-unit.

Reframe pandemic preparedness as global health insurance

Reframe pandemic preparedness as global health insurance

The headlines above the previous several months have been about a scary pathogen, considerations about vaccine availability, and what policymakers are doing to prepare ought to this turn into a common pandemic. No, these are not revisiting the news three a long time back. Fairly, the modern headlines about H5N1 Avian influenza circulating in mammal populations are much more reminders that novel pathogens, pandemics and biothreats are here to continue to be. 

The new Congress has an prospect to reinvest in the nation’s health and fitness infrastructure and greater place the country for the subsequent pandemic. This signifies, first, putting politics aside and, next, on the lookout to fortify pandemic preparedness. Whilst the former might be difficult, looking to advance the latter may well offer a auto to accomplishing better preparedness outcomes for our nationwide safety, economic prosperity and the region as a complete.  

According to the International Monetary Fund, the COVID-19 pandemic could cost the international economic system upwards of $12.5 trillion dollars by means of 2030 — a simply staggering amount of money of funds. With the globe heading to additional “zero sum” results as The Economist indicates, obtaining intelligent techniques of investing at home and making certain economic resilience will lead to not just far better development, but stronger development. 

It is fitting that policymakers converse of prescribed drugs and biotech now in the identical breath as semiconductors and other large-tech provide chains. They too are essential motorists of economic power, though also vital to our nationwide stability. For pandemic preparedness, this signifies hunting at crucial investments not as sunk prices, but as an coverage coverage that will, inevitably, be drawn on in the long run, no matter if artifical or pure in origin.  

Too frequently Congress has seen pandemic preparedness as a luxury at best or basically a sunk expense at worst — a little something that can be eradicated when the risk or menace is lowered or gone. This has found our country lurch from disaster to crisis, accelerating investing in the experience of an emergent condition only to cut down the costs or even zero out paying once the menace has passed. This inconsistent funding is mirrored in our reaction to novel conditions — small is carried out at 1st and then every thing is done all at at the time. This is a high-priced and dangerous technique to disorder administration. Even even worse, if we start off to see pandemic preparedness and response as a result of a political lens, we become divided on an situation related to the fundamental wellness of our country — and our skill to protect ourselves. 

As a starting issue, bad coverage provokes scattered responses and — irrespective of important attempts to the contrary — uncoordinated responses. We have the classes learned, irrespective of whether from SARS, Ebola, Swine Flu, H5N1, and now COVID-19 — the problem is not a scarcity of clever concepts, it is a scarcity of political will and a necessary framework. We have to have to look at pandemic ailment not as a collection of isolated incidents or mishaps but as a very long-phrase management problem that does, from time to time, need an elevated response.  

The begin-quit, all-in or all-out pandemic preparedness method sends the wrong alerts to the private sector which, though not wholly reliant on the federal government, does glance to the federal government for course and regular investment for stockpiling and producing. We are not suggesting that the government subsidize industrial growth, but that commitments are produced to preparedness all over which the private sector can prepare, compete and innovate. Here, all can understand classes from the Trump administration’s Procedure Warp Speed to the Biden administration’s subsequent vaccine and booster rollouts.  

In the long run although sources can come from Washington, we have to remember that care will be offered by state and area authorities and medical doctors, nurses, and EMTs on the pandemic entrance line. The federal federal government with its scale and resourcing is the metaphorical 800-pound gorilla in the room — it can do matters providers and even state and nearby governments can not.  

Nonetheless, it lacks the agility, adaptability and neighborhood/issue make any difference knowledge that the non-public sector, states and localities have. By investing in pandemic preparedness at this amount we can cut down the stress on the federal governing administration, and empower these at the issue of treatment. This usually means encouraging stockpiling at a area degree and augmenting local health care methods and networks. Below the federal authorities can use its dimensions and scale to get improved charges from private sector corporations, give direction for state and neighborhood communities and present a coordinating functionality in the occasion of a crisis.  

When we might experience extensive removed from COVID-19 the virus, its effects and its legacies are incredibly substantially with us. Placing the acrimonious politics to the aspect, we are even now registering bacterial infections, albeit at considerably-lowered rates and with much a lot less virulence and lethality. 

Now is not the time to come to be idle or complacent basically mainly because the immediacy of the danger has ebbed. Instead, it is the time to mirror on what worked and what didn’t, to double down on required reforms and prepare for the next sickness.

Glenn Nye is the president and CEO of the Middle for the Examine of the Presidency & Congress (CSPC). Dan Mahaffee is the senior vice president & director of Plan at the Centre for the Examine of the Presidency & Congress, exactly where he sales opportunities its Geotech Program.

SEP demands billions for health and education, not for war

SEP demands billions for health and education, not for war

The New South Wales (NSW) state election next month is being held amid an unprecedented crisis of the public healthcare and education systems, in the state and across the country. Decades of funding cuts, and now the consequences of bipartisan “let it rip” COVID policies, have brought the public schools and hospitals to a breaking point.

Striking NSW teachers at Sydney rally in May, 2022. [Photo: WSWS]

Public school classrooms and entire schools are chronically overcrowded, while overworked teachers are leaving the profession in droves. The situation in health is deteriorating by every metric, with ambulance and emergency wait times at record levels, and nurses forced to work gruelling shifts while being denied decent pay amid a cost-of-living crisis.

In this election, Labor and the Liberal-National Coalition are making various phoney funding promises. But even if met, they will not resolve what is increasingly an existential crisis for these key social services. Moreover, after the election, the agenda of whichever parties form government will be to slash spending further, in line with a growing budget deficit that already sits at over $200 billion.

While there is supposedly no money to meet the most fundamental needs of the population, spending on the military and war has reached record proportions. While that is primarily at the federal level, it impacts developments in all the states.

The federal Labor and Coalition governments, while allocating vast sums to the war machine, have been reducing or keeping stagnant their funding contributions to education, health and other areas of social spending. The drive to slash spending at the state level, moreover, contributes to the process whereby an ever-greater proportion of total government funds are allocated to the military.

In the NSW election, and more broadly, the Socialist Equality Party (SEP) is alone in raising the call, billions for education and health, not for war!

The SEP’s election campaign is fighting to help develop an international anti-war movement of the working class against the US-led conflict with Russia in Ukraine and preparations for a catastrophic war against China, both of which are supported by Australian governments. The fight against war must be connected to the struggle for the social rights of the working class, including high-quality, free public healthcare and education for all, and decent jobs and wages for all staff in both sectors.

Both Labor and the Coalition are committed to military spending of at least $575 billion this decade, a figure they are already on track to meet. But with plans for the acquisition of nuclear-powered submarines, hypersonic missiles and other advanced weapons systems, that figure is only an initial downpayment.

The sharp contrast between the vast sums handed to the military and the pitiful spending on essential social services was summed up in the federal Labor government’s October budget.

A Ukrainian soldier fires an NLAW anti-tank weapon during an exercise in the Joint Forces Operation, in the Donetsk region, eastern Ukraine, Tuesday, February 15, 2022. [AP Photo/Vadim Ghirda]

It boosted defence spending by 8 percent on the previous financial year, to $52.2 billion. But amid an ongoing global pandemic and health crisis, the budget revealed that federal funding for public hospitals would decrease by $755 million this financial year and $2.4 billion over four years. The budget lowered the federal share of healthcare funding from 50 to 45 percent and reinstated a 6.5 percent annual cap on federal hospital funding, under conditions where official inflation was already above that level, there is an ageing population and increased demands on the hospital system due to the impact of the COVID pandemic and Long COVID.

Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials

Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials

The burden of neurological disorders is growing in the US and abroad, with neurological conditions representing the most frequent cause of disability worldwide1. The resulting consequences are considerable individual suffering and substantial societal healthcare costs2,3. R&D investments are needed to identify new therapies, but clinical research faces challenges including high costs, administrative hurdles, and challenging patient recruitment4,5,6. Furthermore, clinical trials and their associated follow-up visits burden patients and their relatives7, especially for those with highly disabling neurological diseases.

Against this backdrop, the use of digital tools, such as connected sensors, promises to make research more patient-centered and move clinical trials beyond single “snapshots” of disease status toward more continuous measurement of chronic disorders8. Connected digital products9 or Digital Health Technologies (DHTs)10,11 are software-containing, patient-focused, portable, and connected sensors of health-related measurements, which describe different products, including many wearables. DHT examples from current FDA guidance include spirometers with smart connectivity, consumer activity trackers, and mobile applications for patients to report outcomes11. Such connected sensors may improve both the quantity and quality of data collection during clinical trials and enable patient recruitment in a less burdensome and more patient-empowering remote setting9.

In neurological diseases such as Parkinson’s disease (PD), use of validated, reliable, and sensitive tools has already been shown to provide better data on the “real-life distribution of disease severity, as it fluctuates longitudinally” in early-stage patients12,13. DHTs can therefore facilitate new study designs12, improve the efficiency of clinical trials14,15,16, and contribute to tackling many of the challenges neurological research faces. As more researchers adopt such technologies, understanding the use and development of DHTs in neurological clinical trials will be valuable for investigators, practicing clinicians, and those designing patient care pathways. As such, this study documents trends in the use of DHTs in neurology research and highlights opportunities for both R&D activities and care delivery going forward.

We assessed studies registered on ClinicalTrials.gov for four exemplary chronic neurological disorders. Building on methods from Marra et al. (2020)9, we identified trial-indication pairs for clinical studies in epilepsy, the neuroinflammatory disease multiple sclerosis (MS), and the two neurodegenerative diseases, PD and Alzheimer’s disease (AD). We present quantitative and qualitative (categorical) analyses of the trials that used connected sensors to describe technology adoption in neurology research and outline underlying trends over the years 2010-2021, inclusive.

Of the 6763 trial-indication pairs for epilepsy, MS, AD, and PD considered, 503 trial-indication pairs were identified as using DHTs by our search algorithm. After manual verification, 441 trial-indication pairs, associated with 430 unique clinical trials, were determined to be relevant and included in the analysis sample (Supplementary Fig. 1). Analysis sample trial counts varied significantly across indications: most frequent were studies in PD (198, 44.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), followed by MS (119, 27.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), AD (87, 19.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), and epilepsy (37, 8.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}).

We document growth in the use of DHTs in neurological clinical trials, with a compound annual growth rate of ~39{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} from 2010 – 2020, consistent with trends in DHT growth that have been documented in registered clinical studies more broadly9. Most analyzed trials were interventional, with DHT trials based on registries having started only in recent years and typically incorporating some kind of digital activity or speech tracking (Fig. 1).

Fig. 1: Development of clinical trials for chronic neurological diseases by year of initiation, trial type and indication.
figure 1

a Number of analyzed studies using Digital Health Technologies (DHTs) per year, stratified by the type of the respective trial. Line depicts the percentage of DHT trials out of all trials for the analyzed indications starting in the respective year. b Number of analyzed studies using DHTs per year, stratified by the indications epilepsy (Epi.), Alzheimer’s disease (AD), multiple sclerosis (MS), and Parkinson’s disease (PD). * Data for the year 2021 may be incomplete due to late registrations on ClinicalTrials.gov.

The relative frequency of DHT use in trials for the focal conditions increased from 0.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of trials in 2010 to 11.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in 2020. PD trials showed early uptake of DHTs and the highest use rate over the full period of the study (8.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} on average). AD, MS, and epilepsy trials showed a delayed upward trend, with respective use rates of 7.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}, 5.8{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}, and 3.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} overall (Supplementary Table 1).

Among all DHT trials, 16.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} included an industry sponsor or collaborator – slightly less frequently than the 19{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} previously documented across all medical disciplines9 – with industry partnerships more commonly observed in trials for epilepsy (37.8{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) and AD (23.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) (see Supplementary Fig. 2).

With respect to studies’ categorical (qualitative) features, most trials tracked patient symptoms (91.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), with exceptions focusing on vital signs of caregivers or other disease-related outcomes such as medication adherence. The majority of trials measured motor functions (68.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), with many including exercise elements (34.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), sometimes through the use of gaming consoles (7.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}). Sleep (15.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), cognition (10.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), and speech (4.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) tracking were less common as were gamification (19.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), caregiver support (6.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), and medication adherence (4.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) elements (Table 1). A large share of studies used some form of mobile application (35.1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) and the most commonly referenced DHTs were wearables (129, 29.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), smartphones (76, 17.2{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), actigraphs (48, 10.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) and mobile applications (42, 9.5{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) (see Supplementary Table 2).

Table 1 Qualitative (categorical) features of trials by indication.

PD and MS trials often focused on motor symptoms and physical exercise, with a high share of gamification elements in MS trials. Other observed characteristics included numerous caregiver support and speech recognition tools in AD trials, frequent sleep tracking in AD and epilepsy trials, cognition tracking in AD and MS trials, and a recurrent tracking of medication adherence in epilepsy trials (Table 1).

Generally, a trend toward more complex and more extensive studies was observed, as represented by a gradual change in categorical trial features over time (Fig. 2). Whereas the use of motor function and exercise tracking were already observed in 2010, speech and cognition tracking were not observed until the mid-2010s (Fig. 2). Speech and cognition tracking both grew over time and were present in 8.1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} and 14.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of analyzed DHTs using trials in 2021, respectively (Supplementary Table 1). Conversely, the relative use of gamification elements decreased slightly in more recent years (Supplementary Table 1).

Fig. 2: Use of selected Digital Health Technology tracking modalities in trials registered on ClinicalTrials.gov for chronic neurological diseases by year of trial initiation.
figure 2

Number of ClinicalTrials.gov registered trials of four different neurological indications using DHTs for different tracking modalities by trial initiation year (green bar plots). Additionally, rate of these studies compared to all trials for the same indications registered on ClinicalTrials.gov for the respective year is shown (orange line). Trials for the indications epilepsy, Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease were included. a Absolute number and share of all trials for motor function tracking. b Absolute number and share of all trials for sleep tracking. c Absolute number and share of all trials for cognition tracking. d Absolute number and share of all trials for speech tracking. * Data for the year 2021 may be incomplete due to late registrations on clinicaltrials.gov.

Most registered trial-indication pairs were identified in North America or Europe, with a large share of trials having principal investigators in the US (209, 47.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), followed by Italy and France (both 28 or 6.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} each), the UK (19, 4.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Belgium (17, 3.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Switzerland (16, 3.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Israel (14, 3.2{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Canada, Turkey, and Germany (all 13 or 2.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} each). In total, trials from 33 countries and all inhabited continents were included in the analysis sample. Some regions showed a local/regional concentration of DHT studies, often related to a specific indication. An interactive map displaying the locations of sample trials are publicly accessible at https://www.reine-nervensache.de/eigene-forschungsergebnisse/digital-health-technologies-in-neurology-trials.

Qualitatively, included studies displayed heterogeneity in their aims. Whereas some clinical trials aimed to validate products or novel biomarkers, others already applied them as endpoints in studies of other interventions.

While some have highlighted insufficient prospective clinical research applying DHTs and mobile health17, the use of DHTs in neurology trials has not previously been characterized in detail. We analyzed disease-specific DHT adoption in trials registered on ClinicalTrials.gov to provide insights specific to four chronic neurologic diseases.

The analysis confirmed a clear trend in DHT adoption, with some disease-specific heterogeneity. The earlier application of such tools in disorders with primarily motoric symptoms, such as PD or MS, is likely due to the early availability of wearable sensors to track motor functions and might contribute to the higher number of trials observed for these two indications. However, as novel sensors and sophisticated technical setups became available in more recent years, multimodal clinical trials tackling diverse research questions with DHTs began to emerge. This development is evident in the subset of AD trials, where recent growth in the share of trials using DHTs is consistent with increasing readiness of novel digital measures that integrate speech and cognition tracking18,19. In parallel, the repertoire of DHTs used in early-adopting subfields has also expanded, for example through potential PD monitoring technologies that now include passive tremor monitoring via wearables12,13, smartphone-based motor and vocal symptom assessments20,21, gait analysis via smart insoles22, and sensors for swallowing23.

Interestingly, pharmaceutical companies tested self-developed DHTs in some trials24,25,26, indicating a possibility for broader prospective adoption by other stakeholders. Differences in the share of industry-sponsored trials across neurologic diseases could indicate differences in experience with digital measures across indications or difference in research funding for different diseases (either within firms themselves and/or from investments by research foundations or public funders). Any of these factors could shape biopharmaceutical and medical device firms’ investments in their use in clinical trials. Regions with a higher density of clinical trials using DHTs differ in their indication-specificity, suggesting different backgrounds and foci of research teams: high-density areas with multiple indications were more frequent in the US and could indicate technology-driven research, whereas regional clusters focusing on research in a single indication appeared more common in other countries.

Some digital measures assessed in the analysis sample integrate information previously unavailable to clinicians and researchers, such as details of smartphone usage27 or characteristics of patient-caregiver-interactions28,29, in one case deploying real-time monitoring of mood and stress via a smart-home approach29. Monitoring cognitive and motor skills with ‘byproduct data’ such as metadata on smartphone keystroke dynamics, for example, in epilepsy27 or MS30, could allow remote monitoring to be passively and therefore more seamlessly integrated into patients’ daily lives and eventually, into clinical routines. Further examples of the use of previously inaccessible data for novel phenotyping include approaches such as longitudinal repetitive cognitive testing18,31, speech characterization32, or swallowing monitoring23. Especially in more complex recent studies, digital biomarkers or measures were observed in conjunction with biological and radiological biomarkers22,33, promising a more detailed overview of patients’ health status than ever before. Furthermore, the small but growing trend of monitoring and supporting caregivers or relatives via DHTs28,29 could preview new forms of promising assistance for these essential but often neglected alleviators of the burdens of chronic diseases. A personalized prevention of secondary burn-out or depression among caregivers could be supported by DHTs that objectively track interactions with patients and monitor caregivers’ vital signs and stress28,29.

The observed heterogenous use pattern of DHTs in the analysis sample highlights different use cases for validating DHTs, gathering data with DHTs, or using DHTs as interventions; understanding this heterogeneity should be a focus of future research. Examples of trials categorized by the use cases according to Marra et al.9 can be found in Supplementary Table 3. Generally, there appears to be a large variety of new therapeutic and monitoring solutions under study, although solutions often remain fragmented, stand-alone approaches, making it difficult to bring user-friendly, holistic approaches into practice at scale.

The growing share of disease-specific trials applying DHTs show that neurological research is already adapting and increasingly integrating remote digital measurements into its research agenda. In addition to growing adoption of established digital measures, such as motor function, novel approaches, such as speech and cognition tracking are being deployed more often.

Recent regulatory trends further support this development, as seen in the first qualification of a digital endpoint by the EMA in Duchenne muscular dystrophy34, a neuromuscular disorder, and published guidance for applying DHTs by the FDA11. Nevertheless, there remains ample opportunity to extend the use of DHTs in clinical trials and support their transition into routine clinical care. Different technologies promise improved patient healthcare access and new setups for decentralized clinical trials, thereby enabling previously unimaginable measures for gathering real-world evidence. Further research is needed to clarify what is required for broader adoption in practice, thus enabling the translation of verified, analytically validated, and clinically validated tools35 into improved patient care.

Methods

We identified DHTs in trials registered on ClinicalTrials.gov following Marra et al. (2020)9 and using an updated and curated version of the searched product list (see Supplementary Note 1 and GitHub repository in the Data Availability Statement). Additionally, trials were filtered for the conditions epilepsy, MS, AD, or PD, resulting in a dataset built around unique trial-indication pairs (only 10 trials had multiple indications). The analysis sample was restricted to trials launched from 2010–2021 (inclusive) that had at least begun recruitment. Data were retrieved on February 28th, 2022. The resulting set of records was analyzed for the use of DHTs and trials that referenced such products were included in the analysis and mapped to a list of relevant categories defined for this purpose. This list included non-mutually-exclusive features such as different tracking characteristics as listed in Table 1 and Supplementary Table 1 (mapping was carried out by L.M. and P.G.). For comparison, other contemporaneous trials for the same indications were pulled from ClinicalTrials.gov. All analyses were run using Python 3.8 (Python Software Foundation, Delaware, USA). An interactive map of the principal trial locations was generated using plotly version 5.4.036 after geocoding addresses with geopy version 2.2.037. The co-author team included a patient with one of the focal disorders.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.